The development of a preventive vaccine to neutralize the highly variable and antigenically
diverse human immunodeficiency virus type 1 (HIV-1) has been an indomitable goal. The …

After years of continuous exposure to HIV envelope antigens, a minority of HIV-infected
individuals develop a cognate polyclonal humoral response comprising very potent and …

Introduction: This article provides a global overview of patent deposits for broadly
neutralizing antibodies (bNAbs), which have emerged as a key strategy for HIV cure and …

An increasing number of broadly neutralizing antibodies (bnAbs) are considered leads for
HIV-1 vaccine development and novel therapeutics. Here, we systematically explored the …

Developing an effective prophylaxis HIV-1 vaccine is likely to require the elicitation of
broadly neutralizing antibodies (bnAbs). As the HIV-1 envelope (Env) glycoprotein–the sole …

HIV-1 poses immense immunological challenges to the humoral immune response because
of its ability to shield itself and replicate and evolve rapidly. Although most currently licensed …

A prophylactic vaccine would be a powerful tool in the fight against HIV. Passive
immunization of animals with broadly neutralizing antibodies (bnAbs) affords protection …

While accurately predicting archived resistant mutations has been a significant challenge for
bNAb-based treatments, combinations of potent bNAbs against nonoverlapping epitopes …

A large array of broadly neutralizing antibodies (bnAbs) against HIV have been isolated and
described, particularly in the last decade. This continually expanding array of bnAbs has …

In this Review, we highlight some recent developments in the discovery and application of
broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); ie …